Clinical Trials · NCT00512668
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 24
- Start date
- Sep 2007
- Locations
- 1 site, United States
- Primary endpoint
- Safety, in terms of drug-related adverse events of two doses of temsirolimus following androgen ablation